Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Amdipharm UK Limited, Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom
Cyclizine Hydrochloride is indicated in adults and in children aged 6 years and over for the prevention and treatment of nausea and vomiting including:
Cyclizine Hydrochloride may be of value in relieving vomiting and attacks of vertigo associated with Menière’s disease and other forms of vestibular disturbance.
To prevent motion sickness Cyclizine Hydrochloride should be taken about one to two hours before departure.
There have been no specific studies of Cyclizine Hydrochloride in the elderly. Experience has indicated that normal adult dosage is appropriate.
Children less than 6 years of age: Cyclizine Hydrochloride tablets are not recommended for children less than 6 years of age.
Children 6 to 12 years of age: 25 mg orally, which may be repeated up to three times a day.
Children over 12 years of age: 50 mg orally, which may be repeated up to three times a day.
50 mg orally, which may be repeated up to three times a day.
Oral.
Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system.
Peripheral anticholinergic symptoms include dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, incoordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression.
An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg.
In the management of acute overdosage with Cyclizine Hydrochloride, gastric lavage and supportive measures for respiration and circulation should be performed if necessary. Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy.
Shelf life: 5 years.
Store below 25°C.
Amber glass or polyethylene bottles with polyethylene tamper evident caps for pack size 100 tablets.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
